Nocturnal Enuresis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Nocturnal Enuresis Market Outlook
Thelansis’s “Nocturnal Enuresis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Nocturnal Enuresis treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Nocturnal Enuresis Overview
Nocturnal
enuresis (NE) is a condition where an individual involuntarily loses urine
while asleep after the age at which bladder control usually begins. NE can
cause distress to both children and their families, and can have an adverse
impact on behavior, social life, self-esteem, and emotional well-being. NE is
common, especially at school entry age, but will spontaneously resolve in over
50% of children by the time they are 10 years old. The aetiology of NE is
multifactorial and involves social, behavioral, genetic, and clinical factors.
The most common risk factor is genetic/family history. In twin studies,
identical twins showed greater concordance compared with non-identical twins
(68% and 36%). If one parent has childhood NE, around 50% of their children are
affected, increasing to 75% if both parents are affected. Some genetic loci for
NE have been identified. The underlying pathophysiology of NE is understood as
a complex combination of reduced nocturnal bladder capacity and nocturnal
polyuria with sleep arousal difficulties, resulting in enuresis at different
stages of the sleep cycle, not only in deep sleep.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment